July 28, 2016 10:22 PM ET

Biotechnology

Company Overview of Xigen SA

Company Overview

Xigen SA, a biopharmaceutical company, develops therapeutics to inhibit intracellular protein-protein interactions for the treatment of various diseases in the areas of inflammation, central nervous system, oncology, and virology, as well as cancers. Its products include XG-102, a non-ATP competitive peptide based inhibitor of c-jun N-terminal kinase (JNK) that is an intracellular therapeutic target; and XG-102 (AM-111) for acute sensorineural hearing loss. The company was founded in 2002 and is based in Lausanne, Switzerland.

17, rue des Terreaux

Lausanne,  1003

Switzerland

Founded in 2002

Phone:

41 21 321 10 80

Fax:

41 21 321 10 81

Key Executives for Xigen SA

Founder and Director
Chief Financial Officer
Director of Operations and Legal Manager
Head of Chemistry
Head of Cell Biology
Compensation as of Fiscal Year 2016.

Similar Private Companies By Industry

Company Name Region
AB2 Bio Ltd. Europe
AC Immune SA Europe
ADC Therapeutics SA Europe
AlloCyte Pharmaceuticals AG Europe
Amal Therapeutics SA Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Xigen SA, please visit www.xigenpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.